A phase I trial of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) combination on patients with advanced melanoma produced an unprecedented 53% objective response rate (ORR), leading to two-year overall survival (OS) in 79% of cases (NCT01927419) (43). This evidence concerns the gene PDCD1 and melanoma.